Breast cancer
NEW --- Systemic therapy for early stage TNBC

Susanna (51 years old)

Susanna is a 51-year-old CEO at a software company focusing on data science in healthcare. She is always on the lookout for the newest wearables to keep track of her health. She was diagnosed with breast cancer on the right side following screening mammography.

Assessment summary

  • Premenopausal
  • No family history of breast or ovarian cancer
  • No relevant medical history, ECOG PS: 0
  • Tumour size: cT2 (28 mm), LN status: cN0
  • Tumour biology:
    • Ductal invasive carcinoma of NST
    • ER 0%, PgR 0%, HER2 IHC 0
    • Ki67 60%
    • G3
  • Genetic testing: no BRCA1/2 mutation
  • CT scan chest/abdomen and bone scan: no distant metastases
  • Primary systemic therapy: 4 cycles EC dd + 12 weekly paclitaxel
  • BCS + SLNB
  • Pathology report:
    • Residual tumour: ductal invasive carcinoma of NST, ER 0%, PgR 0%, HER2/neu IHC 0, Ki67 15%
    • Stage ypT1N0
    • Residual cancer burden: RCB-II

Which of the following treatment options would you choose for this patient?